Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPLEXA in metastatic solid tumors and hematologic malignancies
NCT05237206Phase 1Completed
- Sponsor
- Alloplex Biotherapeutics
- Start
- Apr 2022
- Primary completion
- Jul 2024
- Modality
- Lymphokine-Activated Killer Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SUPLEXA in metastatic solid tumors, multiple myeloma (MM), lymphoma and 1 more, sponsored by Alloplex Biotherapeutics. Primary endpoint: Safety and Tolerability of SUPLEXA in Subjects With Malignant Solid Tumour and Haematologic Malignancies at 24 months. Started Apr 2022; status: completed.
02
Drugs
SUPLEXA
03
Conditions
metastatic solid tumorsmultiple myeloma (MM)lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05237206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05237206.